Valneva SE: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Valneva SE Announces Sale of its Clinical Manufacturing Operations (CMO) in France to Biological E
Valneva SE announced the signing of a binding term sheet to sell its Clinical Manufacturing Operations (CMO) in Nantes to Biological E, an Indian biopharmaceutical company. The financial terms of the deal were not disclosed.
Latest Developments for Valneva SE
Latest Key Developments in Biotechnology
- Diaxonhit announces positive test results for BJI Inoplex
- Avanir Pharmaceuticals receives Complete Response Letter (CRL) from FDA on AVP-825 NDA
- Affymax Inc. announces special cash distribution and appointment of new director and Chief Executive Officer
- Ablynx NV on track to start Phase III study in patients with acquired TTP in mid 2015
- Share this
- Digg this